Skip to main content
Back
Watch Compare

Lyra Therapeutics, Inc.

Data quality: 100%
LYRA
OTC Manufacturing Measuring & Analyzing Instruments
$0.65
▲ $0.12 (22.64%)
Mkt Cap: 870,402.0
Price
$0.49
Mkt Cap
870,402.0
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue grew 8.71% annually over 5 years — modest growth
Negative free cash flow of -28.98 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 82.76%

Growth

Revenue Growth (5Y)
8.71%
Above sector avg (1.82%)
Revenue (1Y)-74.05%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROIC-64.80%
Net Margin-7266.08%
Op. Margin-7794.47%

Safety

Debt / Equity
N/A
Current Ratio2.43
Interest CoverageN/A

Valuation

PE (TTM)
-0.03
Above sector avg (-1.48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E 0.0 -1.5
P/B — 1.6
ROE % — -53.5
Net Margin % -7266.1 -41.5
Rev Growth 5Y % 8.7 1.8
D/E — 0.3

Analyst Price Target

1 analyst
No analyst coverage available

Earnings Estimates

No forward estimates available

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q32025 -$4.07 -$3.40 +16.5%
Q22025 -$4.78 -$5.22 -9.3%
Q12025 -$6.83 -$6.50 +4.9%
Q42024 -$6.50 -$7.10 -9.2%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -74.05% Revenue Growth (3Y) -49.46%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 8.71% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 398,000.0 Net Income (TTM) -28.92 M
ROE N/A ROA -60.07%
Gross Margin N/A Operating Margin -7794.47%
Net Margin -7266.08% Free Cash Flow (TTM) -28.98 M
ROIC -64.80% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.43
Interest Coverage N/A Asset Turnover 0.01
Working Capital 13.54 M Tangible Book Value -4.33 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.03 Forward P/E N/A
P/B Ratio N/A P/S Ratio 2.19
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -3328.92%
Market Cap 870,402.0 Enterprise Value -21.18 M
Per Share
EPS (Diluted TTM) -18.62 Revenue / Share 0.22
FCF / Share -16.33 OCF / Share -16.26
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 29.15% FCF Conversion 100.19%
SBC-Adj. FCF -32.24 M Growth Momentum -82.76

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 398,000.0 1.53 M 1.56 M 1.36 M 285,000.0
Net Income -28.92 M -93.44 M -62.68 M -55.28 M -43.51 M
EPS (Diluted) -18.62 -1.43 -1.26 -1.83 —
Gross Profit — — — — —
Operating Income -31.02 M -96.35 M -67.12 M -56.31 M -43.62 M
EBITDA — — — — —
R&D Expenses 18.41 M 43.77 M 48.03 M 38.80 M 29.69 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax 11,000.0 39,000.0 59,000.0 13,000.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 36.11 M 66.35 M 142.60 M 109.97 M 54.87 M
Total Liabilities 46.83 M 54.75 M 53.18 M 29.21 M 20.55 M
Shareholders' Equity -10.72 M 11.59 M 89.42 M 80.75 M 34.32 M
Total Debt — — — — —
Cash & Equivalents 15.89 M 40.58 M 22.35 M 32.55 M 45.75 M
Current Assets 16.27 M 43.03 M 104.82 M 100.83 M 47.92 M
Current Liabilities 9.52 M 12.63 M 19.60 M 14.47 M 18.25 M